Laboratorios Farmaceuticos Rovi SA 2023 IR
The report highlights Laboratorios Farmacéuticos ROVI's financial and ESG performance for the fiscal year 2023. The company achieved operating revenue of 829.5 million euros, driven by its CDMO and specialty pharmaceutical businesses. Key milestones included the FDA's approval of ROVI's injectables manufacturing plants for the fill-and-finish of the Moderna COVID-19 mRNA vaccine and the launch of Okedi in several European countries. On the environmental front, the company achieved its goal of compensating 100% of its Scope 1 and 2 emissions and 15% of its Scope 3 emissions, while also expanding its solar self-consumption capacity across its plants.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2023
Type: IR
Pages: 234
Back to company
Laboratorios Farmaceuticos Rovi SA
Integrated Report
The report highlights Laboratorios Farmacéuticos ROVI's financial and ESG performance for the fiscal year 2023. The company achieved operating revenue of 829.5 million euros, driven by its CDMO and specialty pharmaceutical businesses. Key milestones included the FDA's approval of ROVI's injectables manufacturing plants for the fill-and-finish of the Moderna COVID-19 mRNA vaccine and the launch of Okedi in several European countries. On the environmental front, the company achieved its goal of compensating 100% of its Scope 1 and 2 emissions and 15% of its Scope 3 emissions, while also expanding its solar self-consumption capacity across its plants.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees